Home » today » Health » Chula Medicine releases test for potential dementia

Chula Medicine releases test for potential dementia

A blood test for Alzheimer’s markers could provide a 10-year warning that people can use to slow the progression of Alzheimer’s disease, according to the Thai Red Cross Health Science Center for Emerging Infectious Diseases at Chulalongkorn University’s Faculty of Medicine.

BangkokJanuary 30, 2023 /PRNewswire/ — Chulalongkorn University(Chulalongkorn UniversityPoosanu Thanapornsangsuth (Medical Dr.) explained: “Alzheimer’s disease has an incubation period of 10 to 15 years before symptoms appear. By the time symptoms appear, patients may have lost a large number of brain cells, and it is extremely difficult to restore or salvage the brain. Now, we have a medical technology that can detect the presence of the disease well before retirement age, allowing people to take care of themselves and stay away from dementia.”

Chula Medicine releases test for potential dementia

[廣告] please read on

Dementia is incurable and can be caused by many causes and many diseases, but the most important culprit is Alzheimer’s disease, followed by vascular disease. The cause of Alzheimer’s disease is still unclear, and there are many influencing factors, including genetics, environment, pollution, stress, etc.

Dementia and Alzheimer’s disease usually occur in people aged 60 and over, with 1 in 16 people aged 60 and over likely to develop Alzheimer’s, and those aged 80 and over Among the elderly, this proportion increases to 1/6.

There are two traditional ways to check for Alzheimer’s before symptoms appear, PET scans (positron emission computed tomography), and spinal taps and subsequent measurement of levels of Alzheimer’s-causing proteins in the spinal fluid.

Currently, the center uses immunotechniques for blood tests instead of spinal fluid, and analysis is done with Simoa (single molecule immunoarray) or LC-MS (mass spectrometry) detectors that detect phosphorylated Tau (which can indicate potential Al the presence of Alzheimer’s disease), and neurofilament chain (a test for brain cell loss). The project was funded by the Institute of Health Systems Research Institute (HSRI).

This method offers a more affordable solution with less procedural complexity and pain, and an accuracy rate of up to 88%.

Subjects were also required to undergo cognitive tests to assess their “brain reserve.”

Please visit to continue reading.

Media Contact:
Chulalongkorn University Communication Center
e-mail:

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.